Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 314
Selected: 0
NCT IDTitle
NCT04623710Study of ALXN2050 in Participants With Renal Impairment
NCT05047523Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease
NCT02207725A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban
NCT07789483An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy
NCT02112994Safety and Efficacy Study of Sebelipase Alfa in Participants With Lysosomal Acid Lipase Deficiency
NCT00935883Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macular Degeneration (AMD)
NCT02128269Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome
NCT03759366A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)
NCT01095887Eculizumab to Prevent Antibody-mediated Rejection in ABO Blood Group Incompatible Living Donor Kidney Transplantation
NCT03403205Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease
NCT01522183Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
NCT02226146Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid
NCT04560816A Study of the Cardiac Effects of ALXN1840 in Healthy Adults
NCT02293408Natural History Study to Characterise the Course of Disease Progression in Participants With Mucopolysaccharidosis Type IIIB
NCT04248465An Efficacy and Safety Study of Ravulizumab in ALS Participants
NCT00485576Safety and Efficacy Study of Eculizumab in Patients With Mild Allergic Asthma
NCT01180790Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants
NCT07413679Long-term Safety of Danicopan: IPIG Registry-based Cohort Study
NCT07413250Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis of IPIG-Registry Data
NCT03613402BRAVO - Betrixaban Registry Using Real Time Observations in Acute Medical Illness to Assess Venous Thrombosis and Bleeding Outcomes
NCT01203826Extension Study of Protocol ENB-006-09 - Study of Asfotase Alfa in Children With Hypophosphatasia (HPP)
NCT05389449A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH
NCT00122317Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT02113891Eculizumab Therapy for Subclinical Antibody-mediated Rejection in Kidney Transplantation
NCT04725812Complement Regulation to Undo Systemic Harm in Preeclampsia
NCT02946463ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT03131219Study of Ravulizumab in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)
NCT00438789The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol
NCT02235493Non-interventional Substudy of ALX-HPP-502 to Assess Natural History of Patients With Juvenile-onset HPP Who Served as Historical Controls in ENB-006-09
NCT02245412A Phase 2A Study of ALXN1007 in Participants With Newly Diagnosed Acute Lower Gastrointestinal Graft-Versus-Host Disease
NCT03723512Non-contrast Enhanced MRI in Patients With C3 Glomerulopathy (C3G) or Immune-complex Membranoproliferative Glomerulonephritis (IC-MPGN) Enrolled in the ACH471-205 Study
NCT06764160Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Chinese Adults With gMG
NCT05419765Lysosomal Acid Lipase Activity in Nonalcoholic Fatty Liver Disease
NCT01192399Safety and Efficacy Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients
NCT06578949Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adults Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT05876351Eculizumab in Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in China
NCT03661528Trial of Andexanet Alfa in ICrH Patients Receiving an Oral FXa Inhibitor
NCT04889391Study of Radiolabeled Danicopan in Healthy Male Participants
NCT05254613A Study of Single and Multiple SC Doses of ALXN1830 in Healthy Adult Participants
NCT00744042Safety and Efficacy Study of Asfotase Alfa in Severely Affected Infants With Hypophosphatasia (HPP)
NCT02949128Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
NCT00739505Safety Study of Human Recombinant Tissue Non-Specific Alkaline Phosphatase Fusion Protein Asfotase Alfa in Adults With Hypophosphatasia (HPP)
NCT05686564Early Access Program for ALXN1840 in Patients With Wilson Disease
NCT04757259Expanded Access Program for Participants Who Completed Study 13-601 and Continue to Clinically Benefit From Cerdulatinib
NCT02306720Registry of Patients With Hypophosphatasia
NCT05683678US Selumetinib Registry
NCT04970004Study in Adult and Pediatric Patients With HSCT-TMA
NCT06744647Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
NCT04369469Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia
NCT00844428Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUS